TransMedics Group (NASDAQ:TMDX) Earns Hold Rating from Analysts at Stifel Nicolaus

Key Points

• Stifel Nicolaus has initiated coverage of TransMedics Group (NASDAQ:TMDX) with a hold rating and a price target of $115.00, indicating a potential upside of 7.54% from the current price.
• TransMedics recently reported an EPS of $0.92 for the last quarter, exceeding analysts' expectations and showing a revenue increase of 37.7% year-over-year.
• Consensus ratings for the stock show one Strong Buy, five Buy, and four Hold ratings, with an average price target of $122.11.

Stifel Nicolaus initiated coverage on shares of TransMedics Group (NASDAQ:TMDX - Free Report) in a research note published on Thursday morning, MarketBeat reports. The brokerage issued a hold rating and a $115.00 price objective on the stock.

Several other equities analysts have also commented on the company. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $122.11.

TransMedics Group Trading Down 0.0%

Shares of TMDX traded down $0.04 on Thursday, hitting $104.01. 996,736 shares of the stock traded hands, compared to its average volume of 877,429. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $169.29. The stock's 50 day moving average is $118.07 and its two-hundred day moving average is $104.26. The firm has a market capitalization of $3.55 billion, a P/E ratio of 53.89 and a beta of 2.18. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the previous year, the company earned $0.35 EPS. TransMedics Group's revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.00% of the company's stock.

Institutional Trading of TransMedics Group

Several large investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. purchased a new stake in shares of TransMedics Group in the first quarter worth about $25,000. Opal Wealth Advisors LLC acquired a new position in TransMedics Group during the 2nd quarter worth approximately $26,000. Smartleaf Asset Management LLC boosted its holdings in TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after acquiring an additional 135 shares during the period. Quarry LP boosted its holdings in TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. Finally, Sound Income Strategies LLC acquired a new stake in TransMedics Group in the second quarter valued at approximately $48,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.